Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in non-small cell lung cancer
- Trial result
Non-small cell lung cancer
Telisotuzumab vedotin (c-Met ADC) shows similar activity with or without MET amplification in 2L+ EGFR-WT NSQ NSCLC
Telisotuzumab vedotin (Teliso-V) is a c-Met–directed antibody–drug conjugate linking telisotuzumab to the MMAE microtubule inhibitor payload; this retrospective LUMINOSITY (Phase 2; NCT03539536) subgroup analysis…
NCT03539536 - Trial result
Non-small cell lung cancer
Baseline CT QVT (vascular tortuosity) score predicts OS benefit from bevacizumab in 1L metastatic non-squamous NSCLC
In this retrospective biomarker analysis of SWOG S0819 (NCT00946712), QVT (Quantitative Vessel Tortuosity) Score—an automated CT radiomic measure of chaotic tumor vasculature—was derived from baseline scans in…
NCT00946712 - Trial result
Non-small cell lung cancer
Brigatinib (ALK TKI) + AI MRI radiomics predicts longer iPFS vs crizotinib in ALK+ NSCLC brain mets
Brigatinib is a next-generation ALK tyrosine kinase inhibitor (TKI) compared here with crizotinib (first-gen ALK/MET/ROS1 TKI) using AI-powered volumetric + radiomic feature extraction from standard-of-care brain MRI…
NCT02737501 - Trial result
Non-small cell lung cancer
Dabrafenib + trametinib (BRAF/MEK inhibition) shows longer PFS/OS when prior chemo exposure is brief in BRAF V600E mNSCLC
Dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) was evaluated in a post hoc subgroup analysis of the Phase II NCT01336634 sub-cohort B, limited here to patients with metastatic stage IV BRAF V600E NSCLC…
NCT01336634 - Trial result
Non-small cell lung cancer
Sigvotatug vedotin (ITGB6 vedotin ADC) + pembrolizumab drives 50% cORR in 1L aNSCLC across PD-L1
Sigvotatug vedotin (SV; SGN-B6A) is an investigational integrin beta-6 (ITGB6)–directed antibody–drug conjugate using a vedotin (MMAE) microtubule-inhibitor payload, here combined with pembrolizumab (SV 1.8mg/kg IV…
NCT04389632 - Trial result
Non-small cell lung cancer
Amivantamab (EGFR/MET) + lazertinib (EGFR TKI) delivers 41.0-mo OS in 1L atypical EGFR NSCLC
Amivantamab is an EGFR/MET bispecific antibody paired with lazertinib, a third-generation EGFR tyrosine kinase inhibitor, evaluated in Cohort C of the global Phase I/Ib CHRYSALIS-2 study (NCT04077463) in…
NCT04077463 - Trial result
Non-small cell lung cancer
Amivantamab (EGFR/MET bispecific) + carbo/pem doubles PFS vs chemo alone in 1L EGFR exon20ins NSCLC (China subgroup)
Amivantamab is an IV EGFR/MET bispecific antibody designed to block ligand binding/signaling and drive immune-mediated tumor killing; here it was combined with carboplatin–pemetrexed in the randomized, open-label…
NCT04538664 - Trial result
Non-small cell lung cancer
Osimertinib + tegavivint (β-catenin/TBL1 transcription inhibitor) posts 73% ORR and 20.6-mo mPFS in 1L EGFR-mutant NSCLC
Osimertinib (3rd-gen EGFR TKI) was combined with tegavivint, an IV Wnt/β-catenin pathway inhibitor that blocks β-catenin transcriptional activity via TBL1 binding, in a single-arm Phase Ib dose-escalation trial in…
NCT04780568 - Trial result
Non-small cell lung cancer
Ociperlimab (anti‑TIGIT) + tislelizumab (anti‑PD‑1) enriches responses in PD‑L1/TIGIT “double‑high” 1L metastatic NSCLC
Ociperlimab (OCI) is an anti‑TIGIT monoclonal antibody combined with tislelizumab (TIS), an anti‑PD‑1 antibody, in AdvanTIG‑105 (Phase 1/1b, open‑label) in treatment‑naïve metastatic PD‑L1+ (TC ≥1%) NSCLC…
NCT04047862 - Trial result
Non-small cell lung cancer
Olomorasib (KRAS G12C inhibitor) + pembrolizumab drives 58–67% ORR in 1L KRAS G12C NSCLC with PD-L1 0–49%
Olomorasib (LY3537982) is an oral KRAS G12C inhibitor combined here with pembrolizumab (anti–PD-1) as a potential chemotherapy-sparing 1L regimen for KRAS G12C–mutant advanced NSCLC with PD-L1 0–49%. In…
NCT04956640 - Trial result
Non-small cell lung cancer
Silevertinib (BDTX-1535) 4th-gen covalent EGFR TKI posts 36% ORR in EGFR C797S NSCLC
Silevertinib (BDTX-1535) is a fourth-generation covalent EGFR tyrosine kinase inhibitor designed to hit classical EGFR mutations plus non-classical EGFR mutations (including PACC) and acquired C797S, with reported…
NCT05256290 - Trial result
Non-small cell lung cancer
Elisrasib (D3S-001) GDP-bound KRAS G12C inhibitor drives 78%–81% ORR in 1L KRAS G12C NSCLC (±pembrolizumab)
Elisrasib (D3S-001) is an oral next-generation KRAS G12C inhibitor designed to bind the GDP-bound state to improve target engagement and resist growth factor–driven nucleotide exchange, evaluated in a Phase 1/2 study…
NCT05410145 - Trial result
Non-small cell lung cancer
Vabametkib (ABN401), a selective type I c-MET TKI, posts 55% ORR in METex14 NSCLC and pivots to 350mg BID
Vabametkib (ABN401) is an oral, highly selective type I c-MET tyrosine kinase inhibitor being developed for MET-dysregulated solid tumors; this Phase 2, multicenter, open-label study enrolled NSCLC with MET exon 14…
NCT05541822 - Trial result
Non-small cell lung cancer
Alirocumab (PCSK9 inhibitor) + cemiplimab (anti–PD-1) shows biomarker-enriched activity in ICI-refractory metastatic NSCLC
Alirocumab is a monoclonal antibody PCSK9 inhibitor (approved for hypercholesterolemia) being repurposed here to counter immunotherapy resistance, combined with the anti–PD-1 antibody cemiplimab in a first-in-class,…
NCT05553834 - Trial result
Non-small cell lung cancer
PFL-721 (mutant-selective EGFR/HER2 exon 20 TKI) posts 54% ORR in heavily pretreated ex20 NSCLC
PFL-721 is an oral, mutant-selective tyrosine kinase inhibitor designed to inhibit activating EGFR and ERBB2 (HER2) exon 20 alterations while sparing wild-type EGFR, aiming to reduce classic EGFR skin toxicity. In…
NCT06043817 - Trial result
Non-small cell lung cancer
Tremelimumab (CTLA-4) + durvalumab (PD-L1) + chemo extends response durability vs pembrolizumab + chemo in STK11/KEAP1/KRASm 1L NSQ mNSCLC
TRITON (Phase 2b, open-label, US; NCT06008093) randomized treatment-naïve, EGFR/ALK WT, non-squamous mNSCLC with STK11, KEAP1 and/or KRAS mutations (n=84; 41 T+D+pemetrexed-platinum vs 43…
NCT06008093 - Trial result
Non-small cell lung cancer
Olomorasib (KRAS G12C inhibitor) + pembrolizumab maintains ~72–77% ORR despite 1 prior SOC cycle in 1L NSCLC
Olomorasib is an oral covalent KRAS G12C inhibitor combined with pembrolizumab (PD-1) with or without platinum/pemetrexed chemotherapy in 1L advanced KRAS G12C–mutant NSCLC (PD-L1 0–100%, ECOG 0–1) in LOXO-RAS-20001…
NCT04956640 - Trial result
Non-small cell lung cancer
KB707 (inhaled HSV-1 IL-12/IL-2 immunotherapy) + pembrolizumab drives 31% ORR in ICI-experienced aNSCLC
KB707 is a replication-defective HSV-1 vector engineered to deliver intratumoral IL-12 and IL-2 via inhalation, aiming to re-inflame the lung tumor microenvironment and deepen PD-1 blockade responses; here it was…
NCT06228326 - Trial result
Non-small cell lung cancer
TSN1611 (KRAS G12D ON/OFF inhibitor) posts 50% ORR and early intracranial activity in metastatic NSCLC
TSN1611 is a highly selective oral small-molecule KRAS G12D inhibitor designed to bind both GTP-bound (ON) and GDP-bound (OFF) KRAS; in a multi-regional Phase 1/2 dose-escalation/optimization study (NCT06385925),…
NCT06385925 - Trial result
Non-small cell lung cancer
ALK‑Vac peptide vaccine (ALK resistance‑mutation neoantigens) elicits T‑cell responses with 93% disease control on ALK TKIs
ALK‑Vac is a prophylactic synthetic long‑peptide vaccine designed to immunize against seven common ALK kinase–domain resistance mutations (I1171T/N/S, L1196M, G1202R, D1203N, E1210K) and was given with poly‑ICLC…
NCT05950139 - Trial result
Non-small cell lung cancer
RNK08954 (oral KRAS G12D inhibitor) posts 38.5% ORR in pretreated KRAS G12D NSCLC
RNK08954 is a potent, selective, oral small-molecule inhibitor of KRAS G12D evaluated in an ongoing first-in-human, multicenter, open-label Phase 1a/1b study (NCT06667544) enrolling solid tumors with KRAS G12D; this…
NCT06667544 - Trial result
Non-small cell lung cancer
Pumitamig (PD-L1×VEGF-A bispecific) + chemo drives 70% ORR in 1L NSCLC (PD-L1–agnostic)
Pumitamig (BNT327/BMS-986545) is an investigational PD-L1×VEGF-A bispecific antibody intended to combine checkpoint blockade with tumor-localized VEGF-A neutralization, and it was tested with Q3W carboplatin-based…
NCT06712316 - Trial result
Non-small cell lung cancer
DZD6008 (4th-gen EGFR TKI) posts 60% ORR at 60mg in EGFR C797X+ post–osimertinib NSCLC
DZD6008 is an oral, fourth-generation EGFR tyrosine kinase inhibitor designed to inhibit EGFR exon19del/L858R plus resistant double (T790M) and triple mutations including C797X, with reported BBB penetration and…
NCT06905197 - Trial result
Non-small cell lung cancer
HLX43 (anti–PD-L1 ADC) drives 31% ORR in heavily pretreated NSCLC—PD-L1–independent activity
HLX43 is an antibody–drug conjugate (ADC) targeting PD-L1, evaluated in pooled NSCLC cohorts from the Phase 1 HLX43-FIH101 dose escalation/expansion and the global Phase 2 HLX43-NSCLC201 dose exploration/expansion…
NCT06115642 - Trial result
Non-small cell lung cancer
Lorlatinib (ALK TKI) Reaches 55% 7-Year PFS in First-Line ALK+ NSCLC
Lorlatinib is a brain-penetrant third-generation ALK tyrosine kinase inhibitor compared with first-generation ALK/MET/ROS1 inhibitor crizotinib in the Phase 3 CROWN trial for treatment-naïve advanced ALK-positive…
NCT03052608 - Trial result
Non-small cell lung cancer
Encorafenib + Binimetinib (BRAF/MEK) Hits 61% ORR in Chinese BRAF V600E NSCLC
Encorafenib is an oral BRAF inhibitor and binimetinib is an oral MEK1/2 inhibitor evaluated in OCEAN II, an ongoing multicenter, open-label Phase 2 study in China enrolling unresectable stage IV BRAF V600E-mutant…
- Trial result
Non-small cell lung cancer
COPE ctDNA Profiling Raises Genotyping to 97%, but Does Not Improve 18-Month OS
COPE tested serial ctDNA profiling with FoundationOne Liquid CDx plus centralized molecular tumor board review versus tissue profiling and standard imaging in an open-label, randomized, non-comparative Phase 2 trial…
NCT04258137 - Trial result Spotlight
Non-small cell lung cancer
Zoldonrasib (RMC-9805) RAS(ON) KRAS G12D inhibitor drives 52% ORR and 11.1-mo PFS in pretreated NSCLC
Zoldonrasib (RMC-9805) is an oral, covalent, KRAS G12D-selective “RAS(ON)” tri-complex inhibitor that targets the active (GTP-bound) state; updated monotherapy data come from an ongoing Phase 1/1b dose-escalation…
NCT06040541 - Trial result Spotlight
Non-small cell lung cancer
Elisrasib (D3S-001) GDP-bound KRAS G12C inhibitor posts 56% ORR in 2L+ NSCLC and 32% post–G12Ci
Elisrasib is an oral, next-generation KRAS G12C inhibitor designed to bind the GDP-bound state and sustain target engagement despite growth factor–driven nucleotide exchange (a hypothesized resistance lever for…
NCT05410145 - Trial result
Non-small cell lung cancer
Pembrolizumab (PD-1) ± carboplatin/pemetrexed shows manageable grade≥3 toxicity in ≥70yo lung adenocarcinoma
Pembrolizumab is an anti–PD-1 checkpoint inhibitor; here it was given first-line as monotherapy or with carboplatin+pemetrexed in a national, nonrandomized open-label Phase II trial in adults aged ≥70 years with…
NCT04533451
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.